Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 17/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.54 |
| ▸ | SLC6A5 | Q9Y345 | 8/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5556937 | 1.00 | SLC6A9 (0.54) | SLC6A9OPRM1SLC6A5KCNH2OPRL1 | |
| SCHEMBL5556935 | 1.00 | SLC6A9 (0.54) | SLC6A9OPRM1SLC6A5KCNH2OPRL1 | |
| SCHEMBL5562017 | 1.00 | SLC6A9 (0.54) | SLC6A9OPRM1SLC6A5KCNH2OPRL1 | |
| SCHEMBL27668014 | 0.84 | SLC6A9 (0.54) | SLC6A9OPRM1SLC6A5KCNH2OPRL1 | |
| SCHEMBL10740876 | 0.82 | SMN1; SMN2 (0.57) | SLC6A9OPRM1SLC6A5 | |
| SCHEMBL27719321 | 0.79 | SLC6A9 (0.50) | SLC6A9OPRM1SLC6A5KCNH2OPRL1 | |
| SCHEMBL13119224 | 0.78 | HPGD (0.53) | SLC6A9OPRM1SLC6A5KCNH2OPRL1 | |
| SCHEMBL13116655 | 0.78 | HPGD (0.53) | SLC6A9OPRM1SLC6A5KCNH2OPRL1 | |
| SCHEMBL27782824 | 0.77 | SLC18A3 (0.54) | — | |
| SCHEMBL27625961 | 0.77 | SLC18A3 (0.51) | SLC6A9OPRM1SLC6A5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1678177-B1 | TRIAZA-SPIROPIPERIDINE DERIVATIVES FOR USE AS GLYT-1 INHIBITORS IN THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | HOFFMANN LA ROCHE (CH) | 2007-11-28 | — | — | EP | disclosed |
| US-7189850-B2 | E.g., 1-phenyl-8-(2-phenyl-cyclohexyl)-1,3,8-triaza-spiro[4.5]decan-4-one; activation of N-methylaspartic acid receptors via Glycine (Gly t-1) inhibition; psychoses; analgesics; neurodegenerative and psychological disorders; schizophrenia; cognition activators; antidepressants; Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2007-03-13 | — | — | US | disclosed |
| US-7189850-B2 | E.g., 1-phenyl-8-(2-phenyl-cyclohexyl)-1,3,8-triaza-spiro[4.5]decan-4-one; activation of N-methylaspartic acid receptors via Glycine (Gly t-1) inhibition; psychoses; analgesics; neurodegenerative and psychological disorders; schizophrenia; cognition activators; antidepressants; Alzheimer's disease | HOFFMANN-LA ROCHE INC. (US) | 2007-03-13 | — | — | US | disclosed |
| WO-2005040166-A1 | TRIAZA-SPIROPIPERIDINE DERIVATIVES FOR USE AS GLYT-1 INHIBITORS IN THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISORDERS | F.HOFFMANN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |